Los Angeles, USA, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Glioblastoma Multiforme Pipeline Expected to Offer Myriad of Novel Therapies in the Next Decade

Glioblastoma Multiforme Clinical Trial Analysis and Pipeline Assessment report offers an analysis of 120+ companies working for the development of therapies for Glioblastoma Multiforme

DelveInsights Glioblastoma Multiforme (GBM) Pipeline Insight, 2020 report proffers a comprehensive coverage of all the companies under pipeline and growth prospects across Glioblastoma Multiforme pipeline, collaborations and agreements taking place, in-depth commercial assessment, and competitive analysis.

Some of the key highlights of Glioblastoma Multiforme Pipeline Report

Glioblastoma Multiforme pipeline is robust and possesses multiple potential drugs in late and mid-stage developments, which are yet to be launched. 120+ companies are dedicatedly working in advancing the GBM pipeline in the foreseeable future.

Some of the Glioblastoma Multiforme Pipeline Therapies

Regorafenib: Bayer Healthcare

Regorafenib is an orally-administered inhibitor of multiple kinases. Sold under the brand name, Stivarga, Regorafenib is approved for use in patients with hepatocellular carcinoma. The drug is currently under investigation for the treatment of Glioblastoma Multiforme which is mentioned. The molecule is in the phase III stage of clinical development.

CYNK 001: Celularity

CYNK-001 is the only cryopreserved allogeneic, off-the-shelf NK cell therapy being developed from placental hematopoietic stem cells as a potential treatment option for various hematologic cancers and solid tumors. The U.S. Food and Drug Administration (FDA) recently cleared Celularitys Investigational New Drug (IND) Application for CYNK-001 in patients with glioblastoma multiforme (GBM).

Know more about GBM pipeline therapies and product profiles, request @ https://www.delveinsight.com/sample-request/glioblastoma-multiforme-gbm-pipeline-insight

Upcoming Glioblastoma Multiforme Therapies

Scope of Glioblastoma Multiforme Pipeline Therapeutics report

Key Questions regarding Current Glioblastoma Multiforme Treatment Landscape and Emerging Therapies Answered in the report

Table of Contents

Browse Detailed TOC, Emerging Drugs and Key Companies @ Glioblastoma Multiforme Drug Pipeline Landscape

Related Reports

Recurrent Glioblastoma Market

DelveInsight's "Recurrent Glioblastoma - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Recurrent Glioblastoma, historical and forecasted epidemiology as well as the Recurrent Glioblastoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Glioblastoma Market

DelveInsight's 'Glioblastoma - Market Insights, Epidemiology and Market Forecast-2028' report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Glioblastoma in the United States, EU5 (Germany, Spain, Italy, France and the United Kingdom), and Japan.

Adrenocortical Carcinoma Market

DelveInsight's "Adrenocortical Carcinoma - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Adrenocortical Carcinoma, historical and forecasted epidemiology as well as the Adrenocortical Carcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Malignant Glioma Pipeline

Malignant Glioma Pipeline Insight, 2020" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Malignant Glioma market. A detailed picture of the Malignant Glioma pipeline landscape is provided, which includes the disease overview and Malignant Glioma treatment guidelines.

Malignant Glioma Market

DelveInsight's "Malignant Glioma - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Malignant Glioma, historical and forecasted epidemiology as well as the Malignant Glioma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Pediatric brain tumors Market

DelveInsight's "Pediatric brain tumors - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Pediatric brain tumors, historical and forecasted epidemiology as well as the Pediatric brain tumors market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Osteosarcoma Market

DelveInsights Osteosarcoma-Market Insights, Epidemiology, and Market Forecast2030 report deliver an in-depth understanding of the Osteosarcoma, historical and forecasted epidemiology as well as the Osteosarcoma market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Excerpt from:
Glioblastoma Multiforme Pipeline Expected to Offer Myriad of Novel Therapies in the Next Decade - GlobeNewswire

Comments are closed.